

RECEIVED
CENTRAL FAX CENTER
AUG 22 2006

AMENDMENTS TO THE CLAIMS

1. (withdrawn) An isolated polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2.
- 2 (withdrawn) An isolated polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2.
3. (currently amended) An isolated monoclonal antibody that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2.
- 4-23. (canceled)
24. (currently amended) An isolated monoclonal antibody that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2.
- 25-26. (canceled)
27. (previously presented) The antibody of claim 3, wherein the antibody is coupled to a detectable substance.
28. (previously presented) The antibody of claim 24, wherein the antibody is coupled to a detectable substance.
- 29-30. (canceled)
31. (previously presented) A composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier.
32. (previously presented) A composition comprising the antibody of claim 24 and a pharmaceutically acceptable carrier.

33-34. (canceled)

35. (previously presented) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:

- a) an Fab fragment;
- b) an F(ab')₂ fragment; and
- c) an Fv fragment.

36. (previously presented) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:

- a) an Fab fragment;
- b) an F(ab')₂ fragment; and
- c) an Fv fragment.

37. (withdrawn) A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

38. (withdrawn) A composition comprising the polypeptide of claim 2 and a pharmaceutically acceptable carrier.